Basic Information
Jivi
Regulatory Information
EMEA/H/C/004054
Authorised
November 22, 2018
September 20, 2018
5
July 13, 2023
Company Information
Germany
Kaiser-Wilhelm-Allee 1 51373 Leverkusen
BAYER AG
Active Substances Detail
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Treatment and prophylaxis of bleeding in previously treated patients ? 12 years of age with haemophilia A (congenital factor VIII deficiency).
Overview Summary
Jivi is a medicine used to treat and prevent bleeding in patients with haemophilia A, an inherited bleeding disorder caused by lack of a clotting protein called factor VIII. Jivi can be used in adults and children from 12 years of age who have been treated previously. Jivi contains the active substance damoctocog alfa pegol.